Johnson & Johnson scored a one-of-a-kind win for SGLT2 med Invokana in September with an FDA approval to treat kidney disease. Now, as a newcomer to the field, J&J is seeking an experienced hand to help sell its flagging med.
read moreThe UK CBD market is worth £300m currently, and its double-digit growth each year has led to market value expectations of almost £1bn by 2025. More: Trade association launched to ‘drive change’ for CBD regulation Source: News
read moreThe projects are part of the NIHR Research and Innovation for Global Health Transformation (RIGHT) programme. More: NIHR invests £34m into various global health research Source: News
read moreDespite just one in seven of the public actually knowing what the current target in A&E is, although it has been used for 15 years. More: Public show support for ‘rapid’ new A&E measures Source: News
read moreThe companies initially entered an agreement in 2018 as part of LEO Pharma Open Innovation. More: LEO Pharma inks novel compounds deal with Ubiquigent Source: News
read moreThe drive is supported by an additional £56 million funding from Cancer Research UK. More: UK to be ‘transformed’ into radiotherapy research hub Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals